Drug
Rifaximin (drug)
Rifaximin (drug) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%
Ph not_applicable
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Not yet recruiting2
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
unknown125%
not_yet_recruiting250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_3
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
NCT07522255
not_yet_recruitingphase_4
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial
NCT07426705
recruitingnot_applicable
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
NCT06772064
unknownphase_2
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
NCT00281502
Clinical Trials (4)
Showing 4 of 4 trials
NCT07522255Phase 3
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
NCT07426705Phase 4
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial
NCT06772064Not Applicable
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
NCT00281502Phase 2
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4